fangchinoline has been researched along with Cancer of Colon in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Alahmadi, TA; Alharbi, SA; Chinnathambi, A; Jung, YY; Kumar, AP; Sethi, G | 1 |
| Chen, Y; Jiang, F; Li, Z; Piao, D; Ren, S; Zhang, A; Zhang, Z; Zhu, Y | 1 |
2 other study(ies) available for fangchinoline and Cancer of Colon
| Article | Year |
|---|---|
Fangchinoline targets epithelial-mesenchymal transition process by modulating activation of multiple cell-signaling pathways.
Topics: Benzylisoquinolines; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Epithelial-Mesenchymal Transition; Humans; Phosphatidylinositol 3-Kinases; Signal Transduction; Transforming Growth Factor beta | 2022 |
Fangchinoline exerts antitumour activity by suppressing the EGFR‑PI3K/AKT signalling pathway in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drugs, Chinese Herbal; ErbB Receptors; Female; Humans; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |